enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has received a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $24.13.

A number of equities analysts have recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd. UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Morgan Stanley decreased their price objective on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of enGene in a report on Tuesday, March 11th. Finally, Piper Sandler began coverage on shares of enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target on the stock.

Hedge Funds Weigh In On enGene

Institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new stake in shares of enGene in the 4th quarter valued at about $69,000. Jane Street Group LLC bought a new position in enGene in the fourth quarter worth approximately $93,000. Toronto Dominion Bank acquired a new stake in enGene in the fourth quarter valued at approximately $97,000. Cubist Systematic Strategies LLC increased its holdings in shares of enGene by 15.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after acquiring an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. acquired a new position in shares of enGene during the fourth quarter worth approximately $157,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $4.00 on Thursday. The business has a fifty day simple moving average of $5.25 and a 200 day simple moving average of $6.78. enGene has a 12-month low of $3.50 and a 12-month high of $16.62. The firm has a market cap of $203.91 million, a P/E ratio of -6.90 and a beta of -0.38. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.